This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Journal of Hematology & Oncology Open Access 27 July 2020
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sinha, G. Antisense battles small molecule for slice of rare lipid disorder market. Nat Biotechnol 31, 179–180 (2013). https://doi.org/10.1038/nbt0313-179
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0313-179
This article is cited by
-
Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies
Journal of Hematology & Oncology (2020)
-
Spinal muscular atrophy approval boosts antisense drugs
Nature Biotechnology (2017)
-
Induced protein degradation: an emerging drug discovery paradigm
Nature Reviews Drug Discovery (2017)
-
The Role of Antisense Oligonucleotide Therapy in Patients with Familial Hypercholesterolemia: Risks, Benefits, and Management Recommendations
Current Atherosclerosis Reports (2015)